# Agilent Technologies, Inc.: overview

A · NYSE · CIK 1090872 · [Technology](/sectors/technology.md) · fiscal year ends Oct 31

Pages: [Overview](/companies/a.md) · [Financials](/companies/a/financials.md) · [Filings](/companies/a/filings.md) · [Insiders](/companies/a/insiders.md)

Latest reported revenue: [$1.88bn](/filings/0001090872-26-000064.md) for Q3 FY2026, three months to 2026-07-31, from the 10-Q filed Sep 1, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001090872-26-000064).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,701 d](/filings/0001090872-25-000087.md) | [1,681](/filings/0001090872-26-000023.md) | [1,668](/filings/0001090872-26-000055.md) | [1,738](/filings/0001090872-26-000064.md) | [1,861 d](/filings/0001090872-25-000087.md) | [1,798](/filings/0001090872-26-000023.md) | [1,835](/filings/0001090872-26-000055.md) | [1,878](/filings/0001090872-26-000064.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [24.0% d](/filings/0001090872-25-000087.md) | [22.4%](/filings/0001090872-26-000023.md) | [18.0%](/filings/0001090872-26-000055.md) | [20.7%](/filings/0001090872-26-000064.md) | [23.8% d](/filings/0001090872-25-000087.md) | [19.6%](/filings/0001090872-26-000023.md) | [21.7%](/filings/0001090872-26-000055.md) | [23.6%](/filings/0001090872-26-000064.md) |
| Net margin | % | [20.6% d](/filings/0001090872-25-000087.md) | [18.9%](/filings/0001090872-26-000023.md) | [12.9%](/filings/0001090872-26-000055.md) | [19.3%](/filings/0001090872-26-000064.md) | [23.3% d](/filings/0001090872-25-000087.md) | [17.0%](/filings/0001090872-26-000023.md) | [18.5%](/filings/0001090872-26-000055.md) | [19.3%](/filings/0001090872-26-000064.md) |
| Diluted EPS | $ per share | not reported | [1.11](/filings/0001090872-26-000023.md) | [0.75](/filings/0001090872-26-000055.md) | [1.18](/filings/0001090872-26-000064.md) | not reported | [1.07](/filings/0001090872-26-000023.md) | [1.20](/filings/0001090872-26-000055.md) | [1.28](/filings/0001090872-26-000064.md) |
| Free cash flow | $m | [388 d](/filings/0001090872-25-000087.md) | [334](/filings/0001090872-26-000023.md) | [107 d](/filings/0001090872-26-000055.md) | [259 d](/filings/0001090872-26-000064.md) | [452 d](/filings/0001090872-25-000087.md) | [175](/filings/0001090872-26-000023.md) | [201 d](/filings/0001090872-26-000055.md) | [439 d](/filings/0001090872-26-000064.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-10-31) | FY2022 (2022-10-31) | FY2023 (2023-10-31) | FY2024 (2024-10-31) | FY2025 (2025-10-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6,319](/filings/0001090872-23-000020.md) | [6,848](/filings/0001090872-24-000049.md) | [6,833](/filings/0001090872-25-000087.md) | [6,510](/filings/0001090872-25-000087.md) | [6,948](/filings/0001090872-25-000087.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [21.3%](/filings/0001090872-23-000020.md) | [23.6%](/filings/0001090872-24-000049.md) | [19.8%](/filings/0001090872-25-000087.md) | [22.9%](/filings/0001090872-25-000087.md) | [21.3%](/filings/0001090872-25-000087.md) |
| Net margin | % | [19.1%](/filings/0001090872-23-000020.md) | [18.3%](/filings/0001090872-24-000049.md) | [18.1%](/filings/0001090872-25-000087.md) | [19.8%](/filings/0001090872-25-000087.md) | [18.8%](/filings/0001090872-25-000087.md) |
| Diluted EPS | $ per share | [3.94](/filings/0001090872-23-000020.md) | [4.18](/filings/0001090872-24-000049.md) | [4.19](/filings/0001090872-25-000087.md) | [4.43](/filings/0001090872-25-000087.md) | [4.57](/filings/0001090872-25-000087.md) |
| Free cash flow | $m | [1,297](/filings/0001090872-23-000020.md) | [1,021](/filings/0001090872-24-000049.md) | [1,474](/filings/0001090872-25-000087.md) | [1,373](/filings/0001090872-25-000087.md) | [1,152](/filings/0001090872-25-000087.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/a/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $3.40bn | 25,599,001 |  | Reduced −303,661 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.45bn | 18,449,861 |  | Added +68,831 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.92bn | 14,442,441 |  | Added +89,759 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.71bn | 12,854,230 |  | Added +89,598 |
| [MASSACHUSETTS FINANCIAL SERVICES CO /MA/](/funds/912938.md) | 2026-06-30 | $1.36bn | 10,010,867 |  | Reduced −2,613,223 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.00bn | 7,595,644 |  | Added +73,616 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $990.2m | 7,454,686 |  | Added +198,253 |
| [DEUTSCHE BANK AG\\](/funds/948046.md) | 2026-06-30 | $931.0m | 7,008,634 |  | Added +1,024,516 |
| [Bank of New York Mellon Corp](/funds/1390777.md) | 2026-06-30 | $695.2m | 5,233,964 |  | Added +2,440,360 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $688.8m | 5,185,738 |  | Added +236,609 |

## Recent filings

[All 1,658 filings](/companies/a/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-08 | 08:15 ET | [8-K](/filings/0001193125-26-384426.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-384426 |
| 2026-09-01 | 16:11 ET | [10-Q](/filings/0001090872-26-000064.md) | Quarterly report, period 2026-07-31 | 0001090872-26-000064 |
| 2026-08-26 | 16:06 ET | [8-K](/filings/0001090872-26-000062.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001090872-26-000062 |
| 2026-06-25 | 16:23 ET | [8-K](/filings/0001193125-26-282845.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-282845 |
| 2026-06-01 | 16:09 ET | [10-Q](/filings/0001090872-26-000055.md) | Quarterly report, period 2026-04-30 | 0001090872-26-000055 |
| 2026-05-27 | 16:06 ET | [8-K](/filings/0001090872-26-000052.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001090872-26-000052 |
| 2026-05-04 | 08:05 ET | [8-K](/filings/0001193125-26-202636.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-202636 |
| 2026-04-06 | 21:30 ET | [8-K/A](/filings/0001193125-26-142673.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-142673 |
| 2026-04-03 | 16:05 ET | [8-K](/filings/0001193125-26-142101.md) | 5.01 Change in control; 9.01 Financial statements and exhibits | 0001193125-26-142101 |
| 2026-03-20 | 16:05 ET | [8-K](/filings/0001193125-26-117614.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-117614 |

## Latest annual report

[Form 10-K for the fiscal year ended Oct 31, 2025](/filings/0001090872-25-000087.md), filed Dec 22, 2025.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1090872
- Tickers: A
- Exchange: NYSE
- SIC code: 3826 Laboratory Analytical Instruments
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.